Common Equity: The sum of all common equity items.
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) had Common Equity of $84.56M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-14.57M |
|
-- |
|
-- |
|
$15.07M |
|
$-15.07M |
|
$0.42M |
|
$-14.64M |
|
$-14.64M |
|
$-14.57M |
|
$-14.57M |
|
$-14.57M |
|
$-14.57M |
|
$-15.07M |
|
$-14.16M |
|
40.66M |
|
40.66M |
|
$-0.36 |
|
$-0.36 |
|
| Balance Sheet Financials | |
$86.78M |
|
$4.52M |
|
$22.42M |
|
$109.20M |
|
$10.80M |
|
-- |
|
$13.84M |
|
$24.64M |
|
|
Common Equity |
$84.56M |
$69.65M |
|
$84.56M |
|
40.83M |
|
| Cash Flow Statement Financials | |
$-43.74M |
|
$0.41M |
|
$0.00M |
|
$112.40M |
|
$75.67M |
|
$-36.73M |
|
$-0.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-43.32M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-17.23% |
|
-20.92% |
|
-13.34% |
|
-17.23% |
|
$2.07 |
|
$-1.07 |
|
$-1.08 |
|